237 related articles for article (PubMed ID: 23494186)
1. LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?
Besseling J; van Capelleveen J; Kastelein JJ; Hovingh GK
Drugs; 2013 Mar; 73(4):293-301. PubMed ID: 23494186
[TBL] [Abstract][Full Text] [Related]
2. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M
Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124
[TBL] [Abstract][Full Text] [Related]
3. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
4. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
5. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
6. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
7. Is intensive LDL-cholesterol lowering beneficial and safe?
Cheung BM; Lam KS
Lancet; 2010 Nov; 376(9753):1622-4. PubMed ID: 21067806
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
[TBL] [Abstract][Full Text] [Related]
9. Strategies to overcome statin intolerance.
Agouridis AP; Nair DR; Mikhailidis DP
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
[TBL] [Abstract][Full Text] [Related]
10. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
[TBL] [Abstract][Full Text] [Related]
11. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
13. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
14. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins].
Sudhop T; von Bergmann K
MMW Fortschr Med; 2003 Apr; 145(16):48-50. PubMed ID: 14606402
[No Abstract] [Full Text] [Related]
15. Lack of evidence for recommended low-density lipoprotein cholesterol treatment targets.
Modest GA
Ann Intern Med; 2007 Apr; 146(8):614; author reply 614-5. PubMed ID: 17438326
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB;
Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403
[TBL] [Abstract][Full Text] [Related]
17. Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
Soran H; Adam S; Durrington PN
Atherosclerosis; 2018 Nov; 278():135-142. PubMed ID: 30273874
[TBL] [Abstract][Full Text] [Related]
18. [Statins plus cholesterol resorption inhibitor. LDL goal values attainable].
MMW Fortschr Med; 2002 Sep; 144(38):56. PubMed ID: 12395708
[No Abstract] [Full Text] [Related]
19. [Ezetimibe in clinical practice: from laboratory investigations to the IMPROVE-IT trial results].
Borghi C; Filardi PP
G Ital Cardiol (Rome); 2015; 16(7-8 Suppl 1):3S-14S. PubMed ID: 26442834
[TBL] [Abstract][Full Text] [Related]
20. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
Huang JC; Lee TY; Liou MJ; Lin CM; Pei D; Chen ZC; Liu RT; Kwok CF
Curr Med Res Opin; 2011 Aug; 27(8):1645-51. PubMed ID: 21699369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
